Lansheng Biological's application for an IPO on the Shenzhen Stock Exchange has been accepted, filling the domestic gap in the processes for products such as isocamphacetone.
The company has a research and development team of over 140 people. As of the signing of this prospectus, the company has obtained 46 invention patents (including 6 foreign invention patents) and successfully developed various products such as Isocoumarin, with independent intellectual property rights in the synthesis process. Several product processes have filled the domestic gap, and the technology level has reached the international advanced level, possessing strong market competitiveness.
On June 18th, China Securities Co., Ltd. announced that the application for the IPO of Lansen Biochemical Technology Group Co., Ltd. (referred to as Lansen Bio) on the Shenzhen Stock Exchange has been accepted. The company plans to raise 1.68625 billion yuan.
According to the prospectus, Lansen Bio is mainly engaged in the research, development, production, and sales of pesticide active ingredients, formulations, intermediates, and pesticide additives. Its main products include dithiopyr, spirotetramat, cyhalothrin, benzothiazole ketone, and 24-epibrassinolide, covering fungicides, insecticides, herbicides, and plant growth regulators.
The company has a research and development team of over 140 people and has obtained 46 invention patents (including 6 overseas invention patents) as of the signing date of the prospectus. They have successfully developed various products such as cyhalothrin, dithiopyr, spirotetramat, 24-epibrassinolide, quinclorac, benzothiazole ketone, and diphenyl oxazole ethyl. The company has independent intellectual property rights in synthetic processes, with several product processes filling domestic gaps and reaching international advanced levels, demonstrating strong market competitiveness.
The company has actively promoted the automation and continuous production of intelligent manufacturing, equipment continuity, and digital management. They have independently researched and applied advanced equipment including new reactors and efficient extractors, playing a positive role in advanced manufacturing in the industry. Currently, the company has established multiple automated, continuous production lines in four production bases located in specialized chemical industrial parks in Hebei, Inner Mongolia, and Heilongjiang, actively working towards creating unmanned factories, significantly improving the intrinsic safety, stability, and efficiency of production.
During the reporting period, the company's main operating income was as follows:
The company has established long-term stable strategic cooperative relationships with domestic leading agricultural chemical companies such as SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD., NUTRICHEM, Jiangsu Changqing Agrochemical, as well as international renowned manufacturers like BASF, UPL, ADAMA, ALBAUGH. Their products are sold nationwide and in major markets in South America, North America, Europe, and other regions globally.
The company has standardized management and has passed the CNAS laboratory certification, ISO series system certification. It is the vice president unit of the China Agrochemical Industry Association and has been awarded honors such as "Little Giant" enterprise specialized in new products, National Green Factory, Hebei Province Manufacturing Champion Enterprise, Hebei Province Science and Technology Leading Enterprise, and Top 100 Innovative Enterprises in the Strategic Emerging Industry of Hebei Province. The company has set up postdoctoral research workstations, provincial technology innovation centers, provincial enterprise technology centers, and provincial engineering research centers as research and development platforms, winning the 25th China Patent Excellence Award and the 2024 Hebei Science and Technology Progress Award.
In terms of finances, the company achieved operating income of approximately 1.056 billion yuan, 1.494 billion yuan, and 1.836 billion yuan in 2023, 2024, and 2025 respectively. During the same period, net profits were approximately 104 million yuan, 268 million yuan, and 387 million yuan respectively.
Related Articles

From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.

Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.

One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)
From the frenzy on the dark market to the hard work on entering the main market: CREALITY (03388) is holding its ground in the horizontal market.

Hong Kong student dormitory operator Student Living EduVation (SDLV.US) raises fundraising target to $31 million IPO price $4-6 per share.

One picture understanding the Hong Kong Stock Exchange IPO of LB Pharmaceuticals (09637)

RECOMMEND





